S100A9 and rheumatoid arthritis: S100A8/S100A9 levels are useful biomarkers to monitor the disease, and serum concentrations can predict the response to therapeutic drugs such as methotrexate, a commonly used drug for RA treatment, and adalimumab, a TNFα-blocking antibody [56,57,58].